Immunomedics reports phase I/II results of sacituzumab govitecan in gastrointestinal cancers patients
Extended periods of stable disease were also noted in some patients with pancreatic and gastric cancers, with time-to-progression (TTP) exceeding that of last prior therapy in many cases.